<DOC>
	<DOCNO>NCT01685515</DOCNO>
	<brief_summary>The purpose study observe oral tetrahydrouridine decitabine increase fetal hemoglobin level improve symptom sickle cell disease , monitor patient 's body react oral tetrahydrouridine decitabine .</brief_summary>
	<brief_title>Study Decitabine Tetrahydrouridine ( THU ) Patients With Sickle Cell Disease</brief_title>
	<detailed_description>The purpose study observe oral tetrahydrouridine decitabine increase fetal hemoglobin level improve symptom sickle cell disease , monitor patient 's body react oral tetrahydrouridine decitabine . The overall purpose develop disease modify treatment sickle cell disease less cytotoxic current standard care , directly efficiently reactivate fetal hemoglobin level . The hypothesis patient treat oral tetrahydrouridine decitabine chance severe non-hematologic toxicity placebo group . The primary end-point ≥ grade 3 non-hematologic toxicity . The investigator ' hypothesis patient treatment group receive oral THU-decitabine 2X/week 8 week ( n=15 ) equivalent placebo group ( n=10 ) regard chance ≥ grade 3 non-hematologic toxicity .</detailed_description>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Tetrahydrouridine</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Age 18 year old . Written , inform consent provide subject study entry . Confirmed Sickle Cell Disease ( SCD ) ( SS , Sb0thalassemia , Sb+thalassemia SC hemoglobin electrophoresis ) . Symptomatic SCD 6 month HU OR symptomatic SCD intolerant HU ( unable unwilling take HU due hematological toxicity ) . Symptomatic SCD define one following : Fetal Hemoglobin ( HbF ) &lt; 5 % , OR 3 pain episode per year require parenteral narcotic , OR 1 acute chest syndrome episode , OR Hemoglobin &lt; 9 g/dL absolute reticulocyte count &lt; 250,000/mm3 . Subject his/her steady state amidst acute complication due SCD ( i.e. , hospitalization , acute pain , acute chest syndrome past 14 day ) . Regular compliance comprehensive care previous therapy . Inability give inform consent . Experienced severe sepsis septic shock within previous 12 week . Last HU dose ingest within previous 4 week . Currently pregnant breastfeeding . Alanine aminotransferase ( ALT ) great equal two time ( 2X ) upper limit normal albumin &lt; 2.0 mg/dL direct ( conjugate ) bilirubin great equal 1.5 mg/dl . Serum creatinine &gt; 2.9 mg/dL calculate creatinine clearance &lt; 30 mL/min . Platelet count &gt; 800 x 109/L . Absolute neutrophil count &lt; 1.5 x 109/L . Female active childbearing potential unwilling use least one two follow form birth control : ( ) heterosexual sexual contact begin screen visit continue 4 week last dose THUdecitabine OR ( ii ) intrauterine device ( IUD ) . Sexually active male unwilling use condom engage sexual contact female childbearing potential , begin screen visit continue 4 week take last dose THUdecitabine . This requirement apply also male successful vasectomy . Altered mental status recurrent seizures require antiseizure medication . Moribund concurrent disease ( e.g. , hepatic , renal , cardiac , metabolic ) severity death within 24 week likely . Concurrent diagnosis malignancy include myelodysplastic syndrome ( MDS ) , leukemia , abnormal karyotype . VitaminB12 , folate , iron deficient ( correct ) . New York Heart Association ( NYHA ) class III/IV status . Eastern Cooperative Oncology Group ( ECOG ) performance status great equal 3 . Participant chronic transfusion therapy ( e.g. , history Transient Ischemic Attack ( TIA ) stroke ) medically contraindicate discontinue transfusion ( unless multiple alloantibody prevent patient get transfusion schedule ) . Known history illicit drug alcohol abuse within past 12 month . Other experimental investigational drug therapy past 28 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>